CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Get Off on the Right Foot: How to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing.
Get Off on the Right Foot: How to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本综述旨在总结已报道的用于优化单采并确保患者安全的一系列措施。
背景:主要药品监管机构已批准CAR-T 用于部分B细胞淋巴增殖性疾病,应用范围不断扩大且新适应证将陆续获批。单采收集足够单个核细胞和T细胞,是后续CAR-T 制造的关键步骤。单采中心需充分准备,以最高效率并保障患者安全地收集所需细胞。概要:多项研究评估了影响CAR-T 制造T细胞采集效率的不同特征,也尝试识别总靶细胞收集量的预测因素。尽管已有相关文献且临床试验众多,单采领域仍缺乏共识方案。核心信息:本综述总结优化单采和保障患者安全的已述措施,并提出一种实用方法,说明如何将这些知识应用于单采病房日常工作。
BACKGROUND: The major drug regulatory agencies have approved chimeric antigen receptor (CAR) T cells for the treatment of some B-cell lymphoproliferative diseases. Their use is expanding, and new indications will be approved. Efficient mononuclear cell collection by apheresis providing enough T cells is a critical step in further CAR T-cell manufacturing process. It is important that apheresis units are prepared for the collection of the required T cells for manufacturing with the highest efficiency and safety for the patient. SUMMARY: Several series have studied different characteristics that could influence the collection efficiency of T cells for CAR T-cell manufacturing. Also, an effort has been made to identify predictors of the total number of target cells collected. Despite these publications and the large number of ongoing clinical trials, consensus protocols in apheresis are scarce. KEY MESSAGES: The aim of this review was to summarize the set of measures described to optimize apheresis and ensure patient safety. Moreover, we also propose, in a practical approach, a way to apply this knowledge to the daily routine in the apheresis unit.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。